Lymphoid malignancies encompass a diverse array of hematologic cancers, including various forms of lymphoma and leukemia. Their heterogeneous nature and intricate interplay with surrounding stromal cells have long posed significant challenges for effective disease modeling. Conventional 2D cultures, while simple and cost-effective, fall short in replicating the spatial and mechanical cues essential for authentic tumor behavior. In contrast, 3D culture systems mimic the extracellular matrix, cellular heterogeneity, and oxygen gradients, providing a more physiologically relevant platform. This leap in fidelity results in more predictive models, yielding data that better translate to clinical settings.

The architecture of 3D cultures varies widely, ranging from scaffold-based hydrogels embedded with extracellular matrix components to scaffold-free spheroids and organoids. These systems enable cells to inhabit environments that closely emulate the stiffness, porosity, and biochemical signaling present in vivo. As a result, cell proliferation, differentiation, and drug responsiveness observed in 3D cultures are strikingly similar to patient-derived tissues. Notably, lymphoid malignancies often provoke dynamic remodeling of their niche, a phenomenon more accurately recapitulated in these advanced models, allowing researchers to dissect tumor-stroma crosstalk with high precision.

A key challenge in hematology is the frequent discordance between preclinical findings and clinical outcomes. Drugs that demonstrate efficacy in 2D culture or animal models frequently falter in human trials, underscoring the need for more predictive platforms. 3D culture systems, especially those incorporating patient-derived cells, bridge this translational gap by offering models that better simulate human tumor biology and microenvironmental influences. This advancement facilitates the identification of novel therapeutic targets and the evaluation of drug resistance mechanisms that were previously masked in oversimplified systems.

Several cutting-edge 3D culture modalities are making significant strides in lymphoid malignancy research. Patient-derived organoids, for example, preserve the genetic and epigenetic landscape of the original cancer tissue, enabling personalized medicine approaches. Co-culture systems integrating immune cells and stromal components permit investigation of immune evasion tactics employed by malignant clones. Meanwhile, microfluidic devices—organ-on-a-chip platforms—recreate dynamic fluid flows and nutrient gradients, providing another layer of physiological relevance. These innovations collectively foster a deepened understanding of lymphoid cancer pathogenesis.

The integration of multi-omics technologies with 3D cultures is catalyzing transformative discoveries. Single-cell RNA sequencing and spatial proteomics analyses of 3D tumor models reveal heterogeneous cellular states and uncover rare subpopulations contributing to disease progression and relapse. Such detailed molecular characterization within an accurate microenvironmental context is invaluable for designing targeted interventions. Moreover, real-time imaging and biosensor technologies embedded in 3D cultures enable longitudinal monitoring of cellular responses and metabolic shifts, offering kinetic insights impossible to capture in static 2D models.

From a therapeutic perspective, 3D culture systems are revolutionizing drug screening pipelines. High-throughput screening of chemotherapeutics, targeted agents, and immunotherapies in these platforms offers more robust assessments of efficacy and toxicity. Importantly, resistance mechanisms that arise from cell-cell interactions or extracellular matrix barriers—critical in lymphoid malignancies—are faithfully reproduced, aiding in the identification of combination therapies to circumvent treatment failure. This approach accelerates biomarker discovery and facilitates stratification of patient cohorts to optimize clinical outcomes.

One fascinating aspect of lymphoid malignancies is their dependency on the tumor microenvironment (TME), comprising fibroblasts, endothelial cells, immune infiltrates, and extracellular matrix components. Traditional 2D culture strips away much of this complexity, providing an incomplete picture of disease biology. In contrast, 3D models embed malignant cells within a dynamic, interactive milieu that sustains paracrine signaling, cellular crosstalk, and metabolic interplay. This enhanced microenvironmental mimicry uncovers novel pathways underpinning tumor survival, dissemination, and immune suppression, opening new avenues for therapeutic intervention.

Despite their numerous advantages, 3D culture systems are not without limitations. The increased complexity and cost compared to 2D cultures necessitate optimized protocols and standardization to ensure reproducibility. The integration of multiple cell types requires meticulous cell sourcing and validation to avoid artifacts. Furthermore, the scalability of certain 3D models poses challenges for widespread drug screening applications. However, ongoing advances in biomaterials, automation, and computational modeling are steadily overcoming these barriers, making 3D culture systems increasingly accessible to hematology researchers worldwide.

Importantly, the adoption of 3D culture models in preclinical research is reshaping clinical trial design and patient management. By providing more accurate predictors of patient response, these models could reduce the high attrition rates seen in oncology drug development. Personalized organoid cultures derived from patient biopsies are beginning to inform treatment decisions in real time, embodying the promise of precision medicine. Moreover, the ability to model rare lymphoid malignancies in vitro enhances opportunities for targeted drug development where animal models are lacking or insufficient.

The interdisciplinary nature of 3D culture technology development, involving biomaterials scientists, engineers, chemists, and clinicians, is fostering a vibrant research ecosystem. Collaborative centers specialize in integrating biological data with computational models to simulate tumor growth and predict therapeutic outcomes. Such systems biology approaches complement empirical data, enabling hypothesis-driven experimentation and accelerating discovery. The complexity captured by combining these modalities moves the field closer to replicating the human disease state ex vivo, thus transforming translational hematology.

Looking forward, the integration of artificial intelligence (AI) and machine learning (ML) with 3D culture experimentation holds tremendous potential. Automated image analysis and pattern recognition algorithms can rapidly identify phenotypic changes and drug responses at scale. Predictive models trained on multi-modal datasets derived from 3D systems can uncover hidden correlations and novel biomarkers of prognosis and treatment sensitivity. By enabling data-driven decision-making, these technologies will enhance the precision and efficiency of both research and clinical applications in lymphoid malignancies.

In parallel, innovations in microfabrication and bioengineering are giving rise to increasingly sophisticated organ-on-chip platforms that incorporate vascularization and immune system components. These dynamic models recreate physiological shear stresses and intercellular communications integral to tumor progression and immune modulation. Coupled with real-time biosensing, these systems provide granular control and monitoring, enabling unprecedented probing of hematologic malignancies in an accessible and manipulable setting. Such progress paves the way for transformative insights into cancer biology.

Educational efforts are essential to widen adoption and understanding of 3D culture systems among hematologists and oncologists. Workshops, dedicated courses, and collaborative networks disseminate protocols and best practices, bridging the gap between discovery science and clinical application. Funding initiatives targeting translational research promote integration of 3D models into drug development pipelines, ensuring sustained momentum. As these models become incorporated into standard practice, the landscape of lymphoid malignancy research and therapy is poised for a paradigm shift.

In conclusion, the rise of 3D culture systems represents a revolutionary advancement in modeling lymphoid malignancies. These next-generation platforms bridge longstanding gaps between laboratory models and human disease, faithfully recapitulating the complex tumor microenvironment and cellular heterogeneity. By enabling precise dissection of tumor biology, enhancing drug screening fidelity, and facilitating personalized medicine, 3D cultures are fundamentally reshaping translational hematology. The convergence of bioengineering, molecular biology, and computational analytics heralds a new era of cancer research with transformative potential for patient outcomes.

Subject of Research: Lymphoid malignancies and advanced 3D culture systems in translational hematology

Article Title: Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology

Article References:
Houmera, N., Genestier, L. & Huet, S. Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03487-x

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03487-x (Published 03 June 2026)

The Pew-Stewart Scholar program, now in its twelfth iteration, is a landmark initiative jointly supported by The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. It awards a generous four-year, $300,000 grant to early-career scientists who demonstrate transformative potential in cancer research. Dr. Nam’s selection into this elite cohort underscores the significance of her studies aimed at unraveling the complex molecular mechanisms that govern cancer heterogeneity, particularly within lymphoid malignancies.

Dr. Nam’s research is centered on decoding the genetic and cellular foundations that contribute to the distinctive clinical manifestations of Hodgkin lymphoma compared to non-Hodgkin lymphoma, two biologically and pathologically distinct entities within hematologic cancers. Despite sharing overlapping mutational drivers, these lymphomas diverge dramatically in their tumor microenvironment interactions, immune evasion strategies, and clinical outcomes. Her investigations probe the intriguing phenomenon of B-cell–derived lymphoma cells acquiring neural cell-like features through a process termed “neural reprogramming,” hypothesized to offer these malignant cells a survival and proliferative advantage within the tumor niche.

This neural phenotypic plasticity observed in Hodgkin lymphoma cells represents a novel paradigm in cancer biology. Dr. Nam’s work not only aims to elucidate the molecular circuitry that facilitates this cellular identity shift but also seeks to map the downstream functional consequences that contribute to tumor ecosystem control. The insights garnered could pave the way for innovative therapeutic modalities that target these aberrant signaling pathways, potentially revolutionizing treatment strategies for patients afflicted with Hodgkin lymphoma.

Complementing these efforts, Dr. Maria Cecilia Lira’s research delves into the adaptive resistance mechanisms in glioblastomas, which are highly aggressive brain tumors notoriously refractory to standard therapies. Supported through the Pew Latin American Fellowship—a program designed to bolster the careers of promising researchers from Latin America by funding postdoctoral training in the United States—Dr. Lira’s work integrates cutting-edge molecular biology with translational oncology.

Her projects focus on the synergistic use of radiation therapy combined with immune checkpoint blockade and metabolic inhibition, specifically targeting fatty acid synthesis pathways upon which glioblastomas depend for sustained growth and proliferation. By manipulating these interdependent therapeutic axes, Dr. Lira aims to overcome tumor resistance and enhance treatment efficacy. Importantly, her investigative pathway has already yielded a preliminary patent, illustrating the transformative potential of her research to generate novel clinical applications.

Dr. Lira’s scientific odyssey began in Argentina, where she earned her doctorate in biological sciences from the University of Buenos Aires. Her subsequent move to Weill Cornell Medicine positions her at the vanguard of neuro-oncology research, with mentorship from Dr. Claire Vanpouille-Box fostering an environment ripe for independent investigation. This collaborative and nurturing mentorship model exemplifies how structured yet flexible guidance can accelerate the maturation of emerging scientists into independent principal investigators—a long-term aspiration that Dr. Lira passionately hopes to realize by returning to Argentina to establish her own research laboratory.

Both Dr. Nam and Dr. Lira exemplify how targeted funding programs like the Pew-Stewart Scholars and Pew Latin American Fellows can catalyze novel discoveries by bridging early-career scientific exploration with global collaborative networks. Dr. Nam’s exploration of lymphoma neurobiology enriches the understanding of tumor microenvironment adaptability, while Dr. Lira’s multifaceted approach to glioblastoma therapeutics charts new paths for tackling one of the most lethal cancers known.

The implications of these pioneering projects are vast, offering fresh mechanistic insights into cancer biology and translating into potentially life-saving therapies. These awards not only affirm the high caliber of research conducted at Weill Cornell Medicine but also emphasize the importance of nurturing diverse scientific talent across borders and disciplines.

As cancer research continues to evolve, the integration of multidisciplinary approaches—ranging from genetic and epigenetic analyses to immune modulation and metabolic targeting—will be paramount. The work undertaken by Dr. Nam and Dr. Lira signifies how focusing on tumor plasticity and treatment resistance can unlock key vulnerabilities that have hitherto eluded effective clinical intervention.

The Pew fellowships provide essential resources and recognition, enabling these investigators to expand their research endeavors, establish robust laboratories, and attract the attention of the global scientific community. Looking ahead, the breakthroughs stemming from their studies are poised to redefine therapeutic landscapes for Hodgkin lymphoma and glioblastoma, offering renewed hope for patients worldwide.

Through rigorous investigation and innovative thinking, Dr. Nam and Dr. Lira set a sterling example of how early-career researchers can drive transformational change in oncology. Their stories illustrate the critical role of mentorship, funding, and intellectual curiosity in sustaining a vibrant scientific ecosystem capable of confronting the most challenging biomedical puzzles.

Ultimately, these developments highlight a broader narrative within modern cancer research: that interconnecting fundamental molecular insights with translational applications, supported by international collaboration and visionary funding programs, is indispensable to overcoming cancer’s intricate biology and improving patient outcomes globally.

Subject of Research: Cancer biology focusing on Hodgkin lymphoma and non-Hodgkin lymphoma; glioblastoma resistance mechanisms and therapeutic strategies.

Article Title: Weill Cornell’s Dr. Anna Nam and Dr. Maria Cecilia Lira Honored with 2025 Pew Fellowships for Transformative Cancer Research

News Publication Date: 2024

Web References:

• Dr. Anna Nam profile: https://weillcornell.org/seung-nam-md
• Dr. Maria Cecilia Lira profile: https://vivo.weill.cornell.edu/display/cwid-mcl4004

Image Credits: Weill Cornell Medicine

Keywords: Cancer research, Cancer treatments, Cancer, Hodgkin lymphoma, Non-Hodgkin lymphoma, Glioblastoma, Tumor microenvironment, Neural reprogramming, Immune checkpoint inhibitors, Fatty acid synthesis inhibition, Early career scientists, Pew-Stewart Scholars

Classical Hodgkin lymphoma and other CD30-expressing lymphomas have long been entrenched as therapeutic challenges, particularly when standard regimens fall short in relapsed or refractory presentations. While CAR-T therapies have revolutionized treatment paradigms for B-cell malignancies by reprogramming immune cells to eradicate cancer, their deployment in CD30+ lymphoma patients has encountered obstacles, notably the limited persistence of infused CAR-T cells and rapid disease recurrence. Until now, the field has been constrained by a paucity of rigorous clinical investigations dedicated specifically to these lymphomas, stalling progress in their treatment.

The scientific team at IR Sant Pau employed advanced genetic engineering techniques to overcome these hurdles, culminating in the creation of HSP-CAR30—an optimized CAR-T construct designed to enhance both the longevity and antitumor activity of therapeutic lymphocytes. This refinement includes targeting a more stable epitope on the CD30 protein to prevent tumor immune evasion, a strategy informed by detailed molecular analyses revealing the structural vulnerabilities exploited during earlier therapy failures. This breakthrough holds transformative potential for patient populations previously deprived of effective options.

The Phase I trial enrolled a cohort of ten patients contending with relapsed or refractory classical Hodgkin lymphoma or CD30-positive T-cell lymphoma. Astonishingly, the overall response rate reached 100%, a stark contrast to historical outcomes in heavily pretreated cohorts. Notably, half of the participants achieved complete remission, verified through comprehensive imaging and exhaustive clinical evaluations. According to Dr. Javier Briones, lead investigator and director of Hematologic Oncology at IR Sant Pau, this unprecedented efficacy underscores the potent immune-mediated tumor suppression achievable with HSP-CAR30.

Beyond immediate efficacy, the trial highlighted the remarkable durability of responses, with 60% of patients maintaining remission at a median 34-month follow-up. This sustained disease control aligns with the therapy’s ability to establish long-lived memory T cells in vivo, specifically central memory (TCM) and stem cell-like memory (TSCM-like) subsets, which are known to underpin persistent immunosurveillance. Persistent CAR30+ cells were detectable in a majority of evaluable subjects even one year after infusion, marking a significant advancement over prior CAR-T constructs that succumbed prematurely to cellular exhaustion.

Safety evaluations revealed an encouraging toxicity profile. Treated patients predominantly experienced mild, grade 1 cytokine release syndrome (CRS), and crucially, no instances of neurotoxicity were observed. The absence of dose-limiting toxicities signals that HSP-CAR30 can be safely administered, expanding its therapeutic scope. This safety finding is pivotal for clinical translation, particularly given the fragile condition of patients battling relapsed lymphoma.

Central to the therapy’s efficacy is an innovative manufacturing process that integrates interleukins IL-7, IL-15, and IL-21 during ex vivo T-cell expansion. This cytokine cocktail preferentially promotes the generation of less differentiated memory T cells, conferring enhanced proliferative capacity and longevity upon reinfusion. By fostering a reservoir of potent, self-renewing T lymphocytes, HSP-CAR30 ensures sustained antitumor activity and mitigates premature immunologic attrition that has plagued previous CAR-T approaches.

This strategy coincides with deliberate targeting of a stable, non-shedding CD30 epitope, circumventing a key immune evasion mechanism employed by tumors. Earlier CAR-T therapies inadvertently targeted extracellular domains prone to fragment release, blunting immune recognition and facilitating relapse. The precise epitope selection in HSP-CAR30, backed by structural biology insights, represents an intelligent design shift that effectively barricades the therapeutic cells against tumor escape.

As the investigation progresses, Phase II data have already begun to illuminate the therapeutic horizon. Thirty-two patients have been treated with HSP-CAR30, with an expanded cohort adding ten more subjects to solidify findings. Preliminary analyses indicate that over 55% of these patients achieve complete remission, corroborating Phase I results and reinforcing confidence in this approach. The trial’s expansion aims to validate these promising outcomes within a larger, more diverse patient population.

Experts believe this therapy heralds a paradigm shift in treating refractory CD30+ lymphomas. Dr. Ana Caballero, co-investigator and hematology specialist, asserts that if these findings hold in subsequent larger-scale studies, HSP-CAR30 might establish a new standard of care for patients who have exhausted conventional treatments. The dual capability of potent immediate cytotoxicity combined with prolonged immunological memory offers a durable therapeutic platform.

On the technological front, quality control innovations have been critical. Dr. Laura Escribà, overseeing production quality, highlights the stringent manufacturing protocols that ensure consistency and functionality of the CAR-T cells. The incorporation of advanced cell culture techniques, alongside molecular engineering refinements, enables high-yield production of immunocompetent, long-lived CAR-T cells. These processes underscore the translational viability of HSP-CAR30 as a scalable off-the-shelf treatment for hematological malignancies.

The endeavor’s success owes much to multisectoral support. The Josep Carreras Foundation and Leukaemia Research Institute fortified the project with substantial funding and infrastructure, including the establishment of state-of-the-art cell production units at Sant Pau. Additional backing from institutions such as La Marató de TV3, “La Caixa” Foundation, Carlos III Health Institute, and European Union frameworks was instrumental. These collaborations exemplify how targeted investment in cutting-edge immunotherapy research can accelerate clinical breakthroughs.

In sum, HSP-CAR30 exemplifies the confluence of molecular engineering, immunology, and clinical acumen to surmount longstanding challenges in lymphoma therapy. By generating a reservoir of robust, memory-enriched CAR-T cells targeting a strategically chosen antigenic epitope, this therapy offers new hope for patients suffering from refractory CD30+ lymphomas. Future studies will determine if these groundbreaking Phase I and II results translate into long-term remission and survival benefits on a population scale.

Subject of Research: People

Article Title: HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma

News Publication Date: 29-Apr-2025

Web References:
http://dx.doi.org/10.1182/blood.2024026758

References:
Caballero AC, Ujaldón-Miró C, Pujol-Fernández P, Montserrat-Torres R, Guardiola-Perello M, Escudero-López E, Garcia-Cadenas I, Esquirol A, Martino R, Jara-Bustamante P, Ezquerra P, Soria JM, Iranzo E, Moreno-Martinez M-E, Riba M, Sierra J, Alvarez-Fernández C, Escribà-Garcia L, Briones J. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma. Blood 2025;145:1788–1801.

Keywords: Cancer treatments, T cell lymphoma, Clinical research, Memory T cells, Clinical trials, Gene therapy, Blood diseases